WARREN, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced the appointment of Naseem Amin, M.D., as Chairman of its Board of Directors, effective immediately. Dr. Amin, who has served as an Independent Director since 2015, will succeed Jonathan Peacock, who is retiring from the Company's Board. "It has been a privilege to work alongside the talented Bellerophon team over the past several years and to guide the Company's evolution into a late-stage development company," said Mr. Peacock. "With a number of